Publication at First Faculty of Medicine |
2010
Abstract
Results of ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial), TRANSCEND (Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease) and ADVANCE (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation trial) trials are important for the treatment of diabetic and non-diabetic patients with chronic kidney disease. First of all there is the influence of antihypertensive therapy on urinary protein excretion and glomerular filtration rate.